ASCIA HAE Position Paper and Management Plan

The management of hereditary angioedema (HAE) is evolving, with more options for long-term prophylaxis that are now available. The ASCIA HAE position paper and management plan have been updated to include new treatments and to be consistent with international guidelines. 
The most recent updates in 2022 have been made on pages 9, 10, 16. 20 and 27. 
 
Updated ASCIA HAE Position Paper 2022 - Updated October 2022

New ASCIA HAE Management Plan 2022 (with type in fields), which replaces the ASCIA HAE Action Plan.
pdfASCIA HAE Management Plan 2022103.95 KB

New ASCIA HAE Case Peer Review Form (with type in fields), which needs to be completed when requesting prophylaxis dose increases using a new treatment option - Berinert® SC.
pdfASCIA HAE Case Peer Review Form 202091.69 KB

ASCIA Hereditary Angioedema Position Paper 2022  ASCIA Management Plan HAE 2022  ASCIA HAE Case Peer Review Form 2020

Notice from Cipla regarding supply of icatibant

pdfCipla Icatibant Information109.55 KB

Notice from Takeda regarding delisting of Firazyr (icatibant) from PBS in Australia. 

pdfHCP_letter_Firazyr_PBS_Update_002726.08 KB

For information regarding supply of danazol in Australia please refer to www.allergy.org.au/about-ascia/info-updates/product-supply-update-danazol  
ASCIA HAE Working Party members are listed at www.allergy.org.au/members/committees#wp 

HAE Australasia is a support organisation for people with HAE and their carers in Australia and New Zealand.  For more information visit www.haeaustralasia.org.au 

For information about how ASCIA information for health professionals is developed go to: www.allergy.org.au/about-ascia/website-information

Content updated November 2022

Mod ASCIA Member
Donate to AIFA
go to NAC website
About ASCIA

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links

About ASCIA

ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.

Information Partner

Official Information Partner of Healthdirect Australia